Understanding ALS (Amyotrophic Lateral Sclerosis)
A comprehensive, evidence-based guide to ALS — covering diagnosis, approved treatments, breakthrough research, supportive care strategies, and global resources. Updated with the latest clinical findings.
Navigate the Portal
What Is ALS?
Understanding the biology, types, and diagnostic process
The Biology of ALS
ALS is a progressive neurodegenerative disease affecting both upper motor neurons (brain and brainstem) and lower motor neurons (spinal cord). As neurons die, muscles progressively weaken and waste. TDP-43 protein mislocalization and aggregation is found in 97% of ALS cases and is considered the central pathological hallmark.
Muscle weakness typically begins focally — one limb or in the bulbar region (speech and swallowing) — then spreads to affect all voluntary muscles. The diaphragm and respiratory muscles are eventually affected in all patients.
Types of ALS
- Sporadic ALS (sALS): 90-95% of cases; no clear family history; cause is multifactorial (genetic + environmental)
- Familial ALS (fALS): 5-10% of cases; clear genetic inheritance; most commonly SOD1, C9orf72, TARDBP, or FUS gene mutations
- C9orf72 repeat expansion: The most common genetic cause, accounting for 40% of fALS and 5-10% of sALS cases worldwide
- SOD1 mutations: Second most common; now a target of approved gene therapy (Tofersen/Qalsody)
Key Symptoms
- Progressive limb weakness (arm or leg onset) or bulbar onset (speech, swallowing)
- Muscle cramps, fasciculations (twitching)
- Spasticity (upper motor neuron) and atrophy (lower motor neuron)
- Dysarthria (slurred speech) and dysphagia (swallowing difficulty)
- Respiratory muscle weakness — requires monitoring and NIV
- Cognitive/behavioral changes: up to 50% have some FTD features; 5-10% develop full FTD
- Pain, fatigue, emotional lability (pseudobulbar affect)
ALS is a diagnosis of exclusion — there is no single definitive test. The Gold Coast Criteria (2020 revision) require:
- Progressive motor weakness affecting at least 2 body regions
- Evidence of upper and/or lower motor neuron degeneration
- Exclusion of other conditions that mimic ALS
Key diagnostic tests:
- EMG/nerve conduction: The most important test — shows active denervation and reinnervation
- MRI brain and spine: Rules out structural causes of weakness
- Blood tests: CBC, metabolic panel, autoimmune, thyroid, B12, HIV, heavy metals
- Genetic testing: SOD1, C9orf72, TARDBP, FUS recommended for all patients
- NfL (neurofilament light chain): A blood biomarker now used to track disease progression and validate trial outcomes
Average time to diagnosis is 12 months — often delayed due to symptom variability and rarity. Seek a specialist at an ALS center immediately if ALS is suspected.
Treatments
Approved medications, emerging therapies, and respiratory management
| Drug (Brand Name) | Approved | Mechanism | Evidence |
|---|---|---|---|
| Riluzole (Rilutek) | 1995 (FDA, EMA, worldwide) | Glutamate release inhibitor; reduces excitotoxicity | Extends survival by 2-3 months on average; considered standard of care for all patients |
| Edaravone (Radicava) | 2017 (FDA, Japan, Canada) | Free radical scavenger; reduces oxidative stress | Slowed functional decline in a subgroup of patients in Phase 3; IV or oral formulation |
| Tofersen (Qalsody) | 2023 (FDA accelerated) | Antisense oligonucleotide (ASO) targeting SOD1 mRNA; reduces SOD1 protein | Significantly lowers SOD1 and NfL; approved for SOD1-ALS patients specifically |
| Sodium phenylbutyrate + taurursodiol (Relyvrio/AMX0035) | Withdrawn 2024 | Targets mitochondrial and ER stress pathways | FDA approval 2022; manufacturer withdrew after Phase 3 trial failed to replicate Phase 2 results |
| Mecobalamin (Rozebalamin, high-dose methylcobalamin) | 2024 (Japan only) | Ultra-high dose methylcobalamin (50mg IM); neuroprotection mechanism not fully established | Phase 3 in Japan showed significant survival benefit in early-diagnosed patients; not yet approved outside Japan |
Antisense Oligonucleotides (ASOs)
Following the success of Tofersen (SOD1-ALS), multiple ASO programs are in clinical development targeting C9orf72, ATXN2, and other gene variants. WAVE Life Sciences and other companies are advancing next-generation ASOs with improved delivery and potency. ASOs are delivered by lumbar puncture into the CSF.
Gene Therapy — AMT-162
UniQure's AMT-162 (NCT06100276) is an AAV5 gene therapy delivering a microRNA to silence both wild-type and mutant SOD1. A single intrathecal injection aims to provide durable SOD1 suppression. Phase 1/2 safety trial is actively enrolling SOD1-ALS patients worldwide.
Stem Cell Therapies
Multiple stem cell approaches are in trials: NurOwn (BrainStorm) delivers MSCs secreting BDNF and VEGF; AstroRx (Kadimastem) delivers astrocyte progenitors; and various other approaches inject cells intrathecally. Phase 3 results for NurOwn were mixed; next-generation trials with refined protocols are ongoing.
Brain-Computer Interfaces (BCI)
For patients with advanced ALS who have lost motor function, BCI technologies allow communication and device control through neural signals. Neuralink's N1 implant and Synchron's Stentrode (stent-based, no open brain surgery) have demonstrated remarkable communication restoration in ALS patients who had lost all voluntary movement.
Immunotherapy Approaches
Neuroinflammation plays a major role in ALS progression. COYA 302 (NCT05945394) combines Treg-boosting IL-2 therapy to modulate immune overactivation. RAG-17 is an anti-neuroinflammatory compound in early trials. The HEALEY ALS Platform Trial is evaluating multiple investigational drugs simultaneously.
Microbiome-Based Approaches
Dr. Richard Bedlack (Duke University), through his ALSUntangled program, has documented cases of ALS "reversals" or unusual stability and is investigating whether gut microbiome factors may play a protective role. The BL-001 probiotic (Pendulibacter vulgatus) is in early clinical evaluation based on findings from ALS mouse models.
Non-Invasive Ventilation (NIV/BiPAP)
NIV via mask — typically BiPAP (bilevel positive airway pressure) — is initiated when FVC drops below 50-65% or when symptoms of respiratory insufficiency appear (poor sleep, morning headaches, exertional dyspnea). NIV should be started early; late initiation significantly reduces benefit. Many patients use NIV >16 hours/day in advanced stages.
Cough Assist (Mechanical Insufflation-Exsufflation)
The Cough Assist device delivers positive then negative pressure to simulate a powerful cough and clear airway secretions. Critically important for preventing aspiration pneumonia. Should be initiated when peak cough flow drops below 270 L/min. Used in combination with manually assisted cough techniques.
Respiratory Muscle Training (RMT)
Threshold inspiratory muscle training (threshold IMT) can slow the rate of respiratory decline when started early in ALS. Evidence from randomized trials shows benefit when FVC is above 70%. Must be carefully supervised — overwork weakness is a risk if applied too aggressively.
Tracheostomy and Invasive Ventilation
Permanent tracheostomy with mechanical ventilation (TMV) can extend life indefinitely but requires 24-hour care. The decision is deeply personal and should be discussed early, when the patient can fully participate in decision-making. Advance directives and goals-of-care conversations are a critical part of ALS multidisciplinary care.
Key Questions to Ask
- Should I have full genetic testing (SOD1, C9orf72, TARDBP, FUS)?
- Am I eligible for Tofersen (Qalsody) if I have SOD1 mutation?
- When should I start NIV, and what targets should I monitor?
- What clinical trials am I eligible for?
- Should I have a PEG tube placed while I still have good respiratory function?
- Can you connect me with the HEALEY Platform Trial at Massachusetts General?
- What advance directives and palliative care planning should we discuss now?
The ALS Multidisciplinary Team
ALS clinics provide comprehensive, coordinated care including:
- ALS neurologist — disease management, medications, trials
- Pulmonologist — respiratory monitoring and NIV management
- Speech-language pathologist — speech, swallowing, AAC devices
- Physiotherapist — mobility, exercise, equipment
- Occupational therapist — adaptive devices, home modifications
- Dietitian — nutrition management, PEG tube feeding
- Social worker — resources, palliative care planning, caregiver support
- Palliative care team — symptom management, goals of care
Clinical Trials
Active and recruiting trials worldwide — as of 2024/2025
HEALEY ALS Platform Trial (NCT04297683) — Massachusetts General Hospital
A revolutionary master protocol trial that tests multiple investigational drugs simultaneously in ALS patients using a shared infrastructure. Multiple "regimens" (drug arms) can be added or removed based on interim results. This platform approach dramatically accelerates ALS drug development. Multiple regimens are currently active.
PREVAiLS — C9orf72 Pre-Symptomatic Prevention (NCT04856982)
The first ALS prevention trial — enrolling C9orf72 mutation carriers who do not yet have symptoms. Tests whether early ASO treatment can prevent or delay ALS onset. A landmark trial that could reshape how genetic ALS is managed. Conducted at sites across the US, Canada, UK, and Europe.
ATLAS — SOD1 Pre-Symptomatic (NCT04931862)
Tests Tofersen (Qalsody) in presymptomatic SOD1 mutation carriers. The ATLAS trial has already shown that early Tofersen treatment can dramatically delay ALS onset in high-risk carriers. This represents a major paradigm shift toward pre-symptomatic intervention in genetic ALS.
NurOwn Phase 3b — BrainStorm Cell Therapeutics
A revised Phase 3 trial of NurOwn (autologous MSC-NTF cells) with refined patient selection criteria focusing on earlier-stage patients, where the Phase 2 signal was strongest. Intrathecal injection of cells engineered to secrete neuroprotective factors (BDNF, VEGF, HGF).
AMT-162 — SOD1 Gene Therapy (NCT06100276)
UniQure's AAV5-based gene therapy delivering microRNA targeting SOD1. A single intrathecal injection. Phase 1/2 dose-escalation trial in SOD1-ALS. The appeal: a one-time treatment rather than chronic drug administration. Early safety data expected 2025.
COYA 302 — Treg Immunotherapy (NCT05945394)
Combines low-dose interleukin-2 with rapamycin to expand and activate regulatory T cells (Tregs), which are known to be reduced and dysfunctional in ALS. Neuroinflammation driven by immune dysregulation may accelerate motor neuron death — Treg therapy aims to restore immune balance.
Latest Research
Breakthroughs from 2023-2025
TDP-43 Cryo-EM Structure
Researchers have now solved the 3D cryo-EM structure of pathological TDP-43 aggregates at near-atomic resolution (Science, 2023). This reveals the precise misfolded confirmation of TDP-43 filaments found in 97% of ALS cases — a critical step toward designing drugs that dissolve or prevent these aggregates.
C9orf72 Folate-Sensitive Fragile Site
A 2024 Nature Genetics study discovered that the C9orf72 repeat expansion occurs at a folate-sensitive fragile chromosomal site, explaining why some regions show higher ALS rates. This finding opens new research directions: folate metabolism may influence C9orf72 stability and expression.
NfL as Blood Biomarker
Neurofilament light chain (NfL) measured in blood is now validated as the primary biomarker for ALS progression and treatment response. NfL levels closely correlate with the rate of motor neuron death. It is now being used as the primary endpoint in multiple clinical trials, dramatically reducing required sample sizes.
AI Diagnosis from EMG
A 2024 machine learning study showed that AI analysis of standard EMG recordings can diagnose ALS with greater accuracy than experienced neurologists alone, and can predict disease progression rate. This could dramatically reduce the current 12-month average time to diagnosis — earlier diagnosis enables earlier treatment and trial enrollment.
Gut Microbiome in ALS
Multiple studies have found altered gut microbiome compositions in ALS patients. Dr. Bedlack's ALSUntangled program documented a case of ALS stabilization linked to probiotic use. Animal studies show that Pendulibacter vulgatus supplementation is neuroprotective. The BL-001 probiotic trial is now evaluating this in humans.
ATLAS Trial Breakthrough
The ATLAS trial (Tofersen in presymptomatic SOD1-ALS) showed that starting treatment before symptom onset reduced NfL levels by 80% and dramatically delayed the onset of motor symptoms in high-risk carriers. This is the first time a drug has demonstrated meaningful prevention of ALS onset — a paradigm-shifting finding.
Physiotherapy
Exercise and rehabilitation in ALS — principles and evidence
Neurological Physiotherapy
An ALS-specialized physiotherapist designs individualized programs that adapt as the disease progresses. Assessment covers strength, functional mobility, fatigue levels, and fall risk. The focus shifts over time from strengthening to compensation, adaptive equipment, and caregiver training. Regular reassessment is essential.
Moderate Aerobic Exercise
Moderate aerobic exercise — walking, cycling at low resistance, recumbent cycling — has been shown to slow functional decline compared to sedentary behavior in ALS. The key is moderate intensity: perceived exertion of 12-14 on the Borg scale, never reaching exhaustion. Stop at first sign of significant fatigue.
Aquatic (Hydrotherapy)
Water buoyancy allows patients with significant muscle weakness to exercise safely with minimal fall risk. Warm water reduces spasticity and pain. Aquatic therapy maintains cardiovascular fitness, range of motion, and functional strength. Available at specialized hydrotherapy pools; supervision by ALS-experienced staff is important.
Occupational Therapy
OT is critical throughout ALS progression: adaptive eating utensils, voice-activated home systems, electric wheelchairs and power accessories, home modifications (ramps, grab bars, hospital beds), environmental control units, and eye-gaze communication devices for advanced stages.
Respiratory Muscle Training
Inspiratory threshold muscle training (IMT) slows respiratory function decline when started while FVC is above 70%. Requires careful monitoring — overwork can be counterproductive. Sessions should be brief (15-20 minutes) and never cause significant fatigue. Always conducted under pulmonological supervision in ALS.
Overwork Weakness Warning
Unlike most neurological conditions, pushing through fatigue in ALS can cause irreversible additional muscle damage ("overwork weakness"). Signs to stop: significant fatigue lasting more than 30 minutes after exercise, new weakness, muscle soreness lasting over 24 hours. Always exercise at moderate — not maximum — capacity.
Lifestyle, Nutrition, and Communication
Managing daily life and independence with ALS
High-Calorie, High-Protein Diet
ALS increases caloric demands due to increased energy expenditure from fasciculations and reduced efficiency of muscle use. Target 125-150% of normal daily caloric intake. High protein (1.5-2g/kg body weight) supports muscle mass preservation. Calorie-dense, easy-to-swallow foods should be prioritized as dysphagia develops.
PEG Tube (Percutaneous Endoscopic Gastrostomy)
A feeding tube placed directly into the stomach is recommended when oral intake becomes insufficient to maintain weight, or when aspiration risk becomes significant. Critical timing: PEG should be placed while respiratory function is still adequate (FVC above 50%). Placed too late, the procedure carries significant risk. PEG preserves quality of life and extends survival.
IDDSI Texture Framework
As dysphagia progresses, food textures must be modified to prevent aspiration. The International Dysphagia Diet Standardisation Initiative (IDDSI) provides a standardized framework (Levels 0-7) from thin liquids to regular foods. A speech-language pathologist determines the appropriate texture level using clinical swallowing assessment and videofluoroscopy.
Voice Banking
Voice banking records a large number of speech samples while the patient's voice is still clear, creating a personalized synthetic voice. Services include ModelTalker, VocaliD, and Acapela My-Own-Voice. Voice banking should begin immediately after diagnosis — before any noticeable speech changes. A synthetic voice that sounds like you preserves identity and improves communication quality.
Message Banking
Beyond voice, message banking records personally meaningful phrases, expressions, humor, and stories that can be played back later. Recording "I love you," "Good morning," laughter, and other personal expressions preserves a crucial part of identity. Apps like Snap Core First and Proloquo allow personal message libraries.
AAC and Eye-Tracking Technology
When speech becomes significantly impaired, augmentative and alternative communication (AAC) devices take over. Eye-tracking technology (Tobii Dynavox, Grid Pad) allows full communication, computer access, and environmental control using only eye movements. For patients who lose all motor function, brain-computer interfaces (Synchron Stentrode, Neuralink) can restore communication.
Power Wheelchairs and Mobility
Electric power wheelchairs should be introduced early, while the patient can still learn to operate them independently. Features to consider: tilt-in-space and recline for positioning, ventilator mount, AAC device mount, and power-adjustable headrest. Custom seating and pressure management are critical for preventing pressure sores.
Smart Home and Environmental Control
Voice-activated systems (Amazon Alexa, Google Home), smart plugs, and environmental control units allow patients to control lights, TV, temperature, doors, and phones independently. As speech weakens, switch-activated or eye-gaze controlled systems take over. Early setup prevents loss of independence.
Emerging Communication Devices
Synchron's Stentrode BCI is implanted via a blood vessel (no open brain surgery) and restored reliable communication to ALS patients who had lost all motor function. Neuralink's N1 implant has similarly shown remarkable results in ALS. These technologies are in active clinical trials with an accelerating path toward availability.
Mental Health and Psychological Support
Emotional wellbeing, family support, and palliative care
Prevalence of Psychological Challenges
- Depression: Affects approximately 33% of ALS patients
- Anxiety: Affects approximately 35% of patients
- Pseudobulbar affect (PBA): Uncontrolled laughing or crying; affects 20-50% of patients
- Caregiver burden: Nearly 49% of caregivers experience significant burnout
- Frontal lobe changes: Up to 50% of patients have some behavioral/cognitive change; 5-10% develop frontotemporal dementia (FTD)
Evidence-Based Psychological Interventions
- CBT: Addresses depression, anxiety, and existential distress; adapted for ALS communication limitations
- ACT (Acceptance and Commitment Therapy): Strong evidence for adapting to progressive illness; focuses on values-based living
- Dignity Therapy: A brief, narrative psychotherapy specifically developed for patients with terminal illness; creates a lasting "legacy document"
- Mindfulness-Based Approaches: Reduce anxiety and improve coping; many programs are available online
- Family therapy: Essential for processing shared grief and caregiver burnout
Pseudobulbar Affect (PBA): Characterized by sudden, uncontrollable laughing or crying disproportionate to the situation. Caused by upper motor neuron damage disrupting emotional expression circuits.
- Nuedexta (dextromethorphan/quinidine) — the only FDA-approved treatment for PBA; significantly reduces episode frequency and severity
- SSRIs and TCAs are also used off-label and can help
Depression: SSRIs are the first-line choice; mirtazapine is useful when appetite stimulation is also needed. Methylphenidate is sometimes used for fatigue-related low mood. Psychological therapy is strongly recommended alongside medication.
Palliative care is not "giving up" — it is expert, parallel care focused on quality of life alongside disease management. In ALS, early palliative care integration is associated with longer survival and better quality of life.
- Advance directive discussions: ventilation preferences, PEG tube, CPR, hospitalization goals
- Hospice enrollment (when appropriate) provides significant comfort and family support
- Medical aid in dying (MAID) is legal and available in several countries and US states
- Legacy projects: voice/message banking, video recordings, written letters for family milestones
- Grief support for family before and after bereavement
ALS caregiving is one of the most demanding roles in all of medicine. Caregiver burnout, depression, and social isolation are common. Key support strategies include:
- Respite care (short-term breaks from caregiving) — available through ALS organizations and community programs
- Caregiver support groups through the ALS Association and MNDA
- Home health aide services and personal care attendants
- Professional counseling and therapy for caregivers
- Financial planning and benefits navigation (social work support)
Community Stories
Experiences from people living with ALS and their families
"Being diagnosed with SOD1-ALS was devastating, but it also meant I qualified for Tofersen. After six months, my neurologist told me my NfL levels had dropped dramatically. I don't know how much time it has bought me, but I'm fighting with every tool available."— James, 48, SOD1-ALS diagnosis, on Tofersen since 2023
"We started voice banking six weeks after diagnosis. Now, three years later, my father uses a synthetic version of his own voice to talk to his grandchildren. The technology is imperfect, but hearing 'his' voice saying 'I love you' — that means everything."— Claire, daughter of ALS patient
"The ALS clinic changed everything for us. Before, we were seeing a general neurologist who had maybe three ALS patients. At the clinic, the whole team works together — respiratory, speech, physio, social work — all in one day. I felt like I had an army on my side."— Robert, 61, bulbar-onset ALS, diagnosed 2022
"I enrolled in the HEALEY Platform Trial. Even if the drug doesn't work for me, I'm contributing to research that might help someone else. The monitoring I receive through the trial is exceptional — I actually feel better cared for than before."— Linda, 55, in HEALEY Platform Trial since 2023
Your Action Plan
Critical steps after an ALS diagnosis
Get to an ALS clinic immediately
ALS multidisciplinary clinics provide specialized, coordinated care that has been shown to extend survival by months and significantly improve quality of life. Search for your nearest certified ALS center via the ALS Association (als.org) or MNDA (mndassociation.org). Do not wait — early enrollment in an ALS clinic changes outcomes.
Request complete genetic testing immediately
Genetic testing for SOD1, C9orf72, TARDBP, FUS, and other ALS genes is now standard of care. A SOD1 mutation qualifies you for Tofersen (approved) and gene therapy trials. C9orf72 may qualify you for ASO trials and the PREVAiLS prevention study. Results also enable your family members to be tested and potentially treated preventively.
Discuss respiratory monitoring immediately
Begin regular FVC (forced vital capacity) measurements every 3 months. Discuss the timing of NIV initiation with your pulmonologist or ALS neurologist. Initiate respiratory muscle training while FVC is above 70%. Discuss PEG tube placement timing before respiratory function becomes too compromised for the procedure.
Start voice banking NOW
Voice banking takes weeks of recording effort and must be done before your voice changes significantly. Start immediately — ideally within weeks of diagnosis. Use ModelTalker, VocaliD, or Acapela My-Own-Voice. Simultaneously begin message banking: record personal phrases, laughter, stories, and words of love that will matter deeply in the future.
Explore clinical trials
ALS research is moving faster than at any point in history. Visit ClinicalTrials.gov, the NEALS Consortium (neals.org), and the ALS Association trial finder to identify trials you may qualify for. The HEALEY Platform Trial at Massachusetts General is open nationally. Trial participation provides excellent monitoring and contributes to the field.
Advance care planning — do it early
Have detailed goals-of-care conversations while you can fully participate: ventilation preferences, PEG tube decisions, CPR preferences, hospice wishes, legal advance directives, power of attorney, and financial planning. Your ALS social worker can guide this process. Decisions made early — when you are well — are honored more completely and relieve enormous burden from your family.
Resources and Organizations
Leading international organizations, centers, and tools